ALK F1174L/R1275Q Mutational Analysis (Sequencing) (DISCONTINUED)

Specimen Container	-
Specimen Requirement	1. Formalin-Fixed Paraffin-Embedded block or 2. 10x unstained sections and 1 corresponding H&E slide. Tissue must be non-necrotic, non-cauterised, and must not have undergone acid-based decalcification. Improper storage conditions may additionally compromise nucleic acid integrity.
Orderable as Urgent?	No
Turn Around Time	7 Working days
Testing Laboratory Location	KKH
Laboratory	Molecular Histopathology
Contact Number	6394 1402
Day and Time Performed	Mon – Fri: 0800 hrs– 1700 hrs
Orderable on CPOE?	No
Downtime Form	Molecular Pathology
Additional Information	ALK mutational testing in neuroblastomas is offered preemptively by our department both as a prognostic biomarker, and a potential predictive biomarker for response to crizotinib. Patients with neuroblastomas harboring the ALK F1174L mutation have been reported to have a worse prognosis than those with wild-type ALK¹. Preclinical in vitro studies have shown that the presence of the ALK R1275Q mutation correlates with sensitivity to crizotinib, while the ALK F1174L mutation correlates with resistance to crizotinib. Expected Test Result: ALK p.F1174L & p.R1275Q mutations detected/not detected. The molecular test result must always be correlated with clinical and histopathological findings by an appropriately trained, qualified and experienced pathologist. Quality Assurance: Internal Quality Assurance (KKH DPLM) HT0203

Last Updated - 27 Jun 2025